The most recent guidelines from national organizations [8–10] emphasize the importance of a complete pathology assessment of invasive BC (i.e., tumor size, grade, endocrine receptor status, and HER2 amplification) prior to genomic test selection and therapeutic sequencing, including surgery. This evidence concerns the gene ERBB2 and neoplasm.